Viamet Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Viamet Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013300
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:23
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Viamet Pharmaceuticals Inc (Viamet), a subsidiary of Viamet Pharmaceuticals Holdings LLC is a provider of metalloenzyme inhibitors and antifungal agents. The company offers novel agents to treat both chronic and life threatening fungal infections. Its product pipeline includes clinical-stage compounds VT-1161 and VT-1129 and late-stage preclinical compound VT-1598. Viamet’s VT-1129 is developed for the treatment of cryptococcal meningitis. The company’s technology portfolio includes metalloenzyme target selection, metallophile database and metal-binding, medicinal chemistry, pharmacologic, and counter-screening capabilities. Viamet is headquartered in Durham, North Carolina, the US.

Viamet Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Viamet Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Viamet Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Viamet Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Viamet Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Viamet Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Viamet Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Viamet Pharma Raises USD12 Million in Venture Financing 11
Viamet Pharma Raises USD60 Million in Series D Venture Financing 12
Viamet Pharma Raises US$10 Million In Series C1 Financing 13
Viamet Pharma Secures Additional US$15 Million In Series B Financing 14
Partnerships 15
Viamet Pharma Enters into Agreement with MSGERC 15
Viamet Pharma Enters Into Co-Development Agreement With National Institutes of Health 16
Licensing Agreements 17
Innocrin Pharma Enters into Licensing Agreement with Viamet Pharma for Metallophile Technology 17
Equity Offering 18
Viamet Pharma Withdraws IPO 18
Viamet Pharmaceuticals Inc – Key Competitors 20
Viamet Pharmaceuticals Inc – Key Employees 21
Viamet Pharmaceuticals Inc – Locations And Subsidiaries 22
Head Office 22
Appendix 23
Methodology 23
About GlobalData 23
Contact Us 23
Disclaimer 23

List of Tables
Viamet Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Viamet Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Viamet Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Viamet Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Viamet Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Viamet Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Viamet Pharma Raises USD12 Million in Venture Financing 11
Viamet Pharma Raises USD60 Million in Series D Venture Financing 12
Viamet Pharma Raises US$10 Million In Series C1 Financing 13
Viamet Pharma Secures Additional US$15 Million In Series B Financing 14
Viamet Pharma Enters into Agreement with MSGERC 15
Viamet Pharma Enters Into Co-Development Agreement With National Institutes of Health 16
Innocrin Pharma Enters into Licensing Agreement with Viamet Pharma for Metallophile Technology 17
Viamet Pharma Withdraws IPO 18
Viamet Pharmaceuticals Inc, Key Competitors 20
Viamet Pharmaceuticals Inc, Key Employees 21

★海外企業調査レポート[Viamet Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Minoryx Therapeutics sl:製薬・医療:M&Aディール及び事業提携情報
    Summary Minoryx Therapeutics sl (Minoryx) is a clinical stage biotechnology company that develops treatments for life threatening rare diseases. The company offers discovery, preclinical research, development and clinical trial programs. It develops ALD-MIN, morquio B and PCT drugs used for lysosoma …
  • Children’s Medical Center:企業の戦略的SWOT分析
    Children's Medical Center - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Incitec Pivot Ltd (IPL):企業の財務・戦略的SWOT分析
    Incitec Pivot Ltd (IPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Dassault Systemes SA:企業の戦略・SWOT・財務情報
    Dassault Systemes SA - Strategy, SWOT and Corporate Finance Report Summary Dassault Systemes SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Oil India Limited:企業の戦略・SWOT・財務分析
    Oil India Limited - Strategy, SWOT and Corporate Finance Report Summary Oil India Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • BioMark Diagnostics Inc:医療機器:M&Aディール及び事業提携情報
    Summary BioMark Diagnostics Inc (BioMark Diagnostics) is an oncology-focused medical equipment company that owns and develops multiple intellectual properties in detection and quantitation of metabolites. The company’s advanced near-to- market diagnostic technologies designed to improve patient outc …
  • First Pacific Company Limited:企業の戦略・SWOT・財務情報
    First Pacific Company Limited - Strategy, SWOT and Corporate Finance Report Summary First Pacific Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Pinnacle Entertainment Inc:戦略・SWOT・企業財務分析
    Pinnacle Entertainment Inc - Strategy, SWOT and Corporate Finance Report Summary Pinnacle Entertainment Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Mylan Laboratories Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Mylan Laboratories Ltd (Mylan), a subsidiary of Mylan NV is a pharmaceutical company that manufactures and supplies API products. The company offers HIV care products for the treatment of HIV/AIDS. It provides women’s care products for therapies such as hormone replacement therapy, infertili …
  • CryoLife Inc (CRY):企業の製品パイプライン分析2018
    Summary CryoLife Inc (CryoLife) is a provider of biosurgical devices and implantable living tissues for cardiac and vascular surgical procedures. The company’s portfolio enlists preserved human cardiac allografts, vascular allografts, surgical adhesives and sealants, heart valves, carbon dioxide dif …
  • Cytune Pharma SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary Cytune Pharma SAS (Cytune) is a health care product developer that develops immunotherapeutic agents for the treatment of cancer and infectious diseases. The company’s product portfolio includes recombinant proteins and monoclonal antibodies. Its CYP0150 is a recombinant protein, which decre …
  • Umeme Limited (UMEME):企業の財務・戦略的SWOT分析
    Umeme Limited (UMEME) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Rompetrol Rafinare SA (RRC):企業の財務・戦略的SWOT分析
    Rompetrol Rafinare SA (RRC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Shermco Industries Inc:企業の戦略的SWOT分析
    Shermco Industries Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Alabama Power Co:企業の発電所・SWOT分析2018
    Alabama Power Co - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (e …
  • OSRAM Opto Semiconductors GmbH:企業の戦略的SWOT分析
    OSRAM Opto Semiconductors GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Massachusetts Institute of Technology-製薬・医療分野:企業M&A・提携分析
    Summary Massachusetts Institute of Technology (MIT) is a research university that provides contract research and education. The institute offers education in the areas of computer science, biology, aeronautics, mechanical engineering, civil engineering, economics, electrical engineering, literature, …
  • Eiger BioPharmaceuticals Inc (EIGR):企業の財務・戦略的SWOT分析
    Summary Eiger BioPharmaceuticals Inc (Eiger) formerly Celladon Corp, is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of novel drugs for the treatment of orphan diseases. The company provides pipeline products such as Lonafarnib and Lambda, which ar …
  • FLSmidth & Co AS (FLS):企業の財務・戦略的SWOT分析
    FLSmidth & Co AS (FLS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Forma Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Forma Therapeutics Inc (Forma) is a drug discovery and development company that discovers and develops new transformative cancer therapeutics. The company develops technologies to identify the initial molecules that provide drug discovery program. It offers research in the areas of tumor met …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆